# Secondhand Tobacco Smoke and Cardiovascular Disease

Study · id `cardio:ct-nct04715568` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04715568](<https://clinicaltrials.gov/study/NCT04715568>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04715568

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04715568. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-30 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04715568, source copy `cardio:ctgov-nct04715568-2026-08-19`, retrieved 2026-10-26)
- Started: 2021-03-30 (actual) (ClinicalTrials.gov record NCT04715568, source copy `cardio:ctgov-nct04715568-2026-08-19`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04715568, source copy `cardio:ctgov-nct04715568-2026-08-19`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04715568, source copy `cardio:ctgov-nct04715568-2026-08-19`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04715568, source copy `cardio:ctgov-nct04715568-2026-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04715568-2026-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Secondhand Tobacco Smoke and Cardiovascular Disease
- Condition: Cardiovascular Diseases
- Condition: Hypertension
- Intervention (Drug): Losartan
- Intervention (Drug): Placebo
- Lead sponsor: University of California, San Francisco
- Lead sponsor class: OTHER
- Collaborator: Flight Attendant Medical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: University of California, San Francisco (`cardio:org-university-of-california-san-francisco`)

## Provenance

Content hash: f926bd36ace1e67604b7d72eec314e3dc7fad9069cf963849309ff1581e783b8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
